Stereotaxis

Phase A — Understand the business

Lens 1 · Company Overview

Stereotaxis (St. Louis, MO; NYSE American: STXS; founded ~1990; incorporated Delaware) designs and sells Robotic Magnetic Navigation (RMN) systems for the interventional cath lab — primarily for cardiac electrophysiology (EP), the treatment of arrhythmias via catheter ablation. The system uses two large permanent magnets on articulating arms — one on either side of the patient table — to steer the soft working tip of a magnetic catheter through the heart from a remote control station, instead of the physician manually pushing a stiff catheter.

The pitch to hospitals is three-fold:

1. Safety — the physician sits away from the table, drastically cutting X-ray (fluoroscopy) exposure; the soft magnetic tip reduces perforation risk.
2. Efficiency / standardization — reduces and standardizes procedure times, especially for the most complex cases (e.g. ventricular tachycardia), enabling better scheduling and lower disposable use.
3. Democratization — lets a broader range of physicians perform complex procedures that previously required years of manual dexterity training; the system can be programmed to run navigation sequences automatically.

The business model is razor-and-blade, and that is the whole story for a thesis:

• Razor (systems): the GenesisX RMN, Genesis RMN, and legacy Niobe robots; the Odyssey and Synchrony/SynX information/visualization solutions. Lengthy, lumpy capital sales requiring cath-lab construction/renovation.
• Blades (recurring): proprietary disposable interventional devices — the MAGiC ablation catheter, MAGiC Sweep mapping catheter, Map-iT diagnostics, QuikCAS — plus service/maintenance plans and software. Management's explicit strategy is to "leverage the installed base of systems to drive recurring sales of disposable interventional devices, software and service".

FY2025 revenue $32.4M, +20% YoY, split:

• Systems: $10.2M (+18%)
• Disposables, service & accessories: $22.2M (+21%) — the recurring base is already ~69% of revenue.

Customers: hospitals and EP physicians. No single customer >10% of revenue in 2025 or 2024; no single country other than the US >10%. 131 employees as of Dec 31, 2025 (40 R&D, 47 sales/marketing).

Key payment-term color: the disposables/service revenue is genuinely recurring and contracted (service-type warranties amortized over ~1 year), but the systems side is project-based, cancellable, and contingent on hospital construction timelines. There is no take-or-pay. This is a small-cap, story-driven medtech, not a stable annuity — yet.

Lens 2 · Supply Chain

Upstream → Stereotaxis → end customer, with named chokepoints:

• Permanent magnets (the core of the robot): sourced through purchase orders, not long-term supply agreements, from a small set of vendors that "could discontinue sourcing or supplying these magnets at any time". This is a genuine single-source-ish dependency on the highest-value component.
• Components / major assemblies: mostly bought via purchase orders rather than long-term contracts; the company "generally does not maintain" large component inventories.
• THE catheter dependency — the defining supply-chain fact. Until MAGiC, the ablation catheters used with the RMN system were manufactured by Biosense Webster, a J&J subsidiary ("the J&J catheters"). The J&J supply/royalty agreement expired by its terms on December 31, 2022 (ending royalty income to Stereotaxis), and J&J has not committed to continuing catheter supply into 2026. For years this meant the value-driving disposable in Stereotaxis's own ecosystem was controlled by a competitor. MAGiC is the company's escape from that hostage situation.
• Fluoroscopy / X-ray integration: the RMN needs an integrated X-ray system; Stereotaxis partners with fluoroscopy manufacturers to bundle systems for hospitals. An ongoing risk: maintaining compatibility with third-party imaging/mapping systems it does not control.
• Robocath (pending): adds a Rouen, France manufacturing/R&D footprint for mechanical (guidewire/catheter-pushing) robotics.

Chokepoint verdict: two real single-points-of-failure — the magnet vendors and, historically, the J&J catheter. The MAGiC ramp simultaneously removes the catheter chokepoint and creates a new one — Stereotaxis's own manufacturing capacity. The bottleneck has been internalized, which is strategically correct but means execution risk now sits inside the building.

Lens 3 · Competitive Advantages (moats)

The moat is real but narrow, and it is a moat over a small castle.

• Regulatory + clinical-evidence moat (strongest). RMN in EP is documented in over 500 clinical publications with hundreds of trained electrophysiologists. The full regulatory stack — GenesisX (US/EU), MAGiC (US/EU), MAGiC Sweep (FDA 510(k) July 2025), Niobe (US/EU/Canada/China/Japan) — is a multi-year, multi-geography barrier a new entrant cannot replicate quickly.
• Switching costs / installed-base lock-in. Once a hospital installs an RMN system (a capital purchase requiring cath-lab construction) and trains its physicians, it is structurally committed to Stereotaxis's proprietary disposables. This is the razor-and-blade lock-in — but it only matters at the scale of the installed base, which is modest.
• IP / process. Proprietary magnet-navigation physics, the only commercial magnetic (vs. mechanical) catheter robot at scale; "aware of two other companies that produce magnetically enabled catheters" but none commercially active in catheter robotics.
• Vertical integration (newly completed). Owning the catheter (MAGiC) + the robot (GenesisX) + the information layer (Odyssey/Synchrony) is a closed ecosystem competitors must match piece by piece.

Bargaining power is weak on both sides. Stereotaxis needs hospitals far more than they need it (it is one capital line-item among many, with a long cancellable sales cycle), and it has historically depended on a competitor (J&J) for its key blade and on a handful of vendors for magnets. Net: a durable technical/regulatory moat, but the company has limited pricing power until the installed base and MAGiC volume scale enough to make the recurring base self-reinforcing.

Lens 4 · Segments

Stereotaxis reports two revenue lines (product type), and effectively one geography that matters (US >10%, no other country >10%). No reportable operating segments beyond this — it is a single-business company. All figures ``.

By product type:

The trend that matters — Q1 2026 reversal:

Cause (sourced, not inferred): the systems drop is "decreased sales volume in the current year period"; the disposables drop is explicitly "lower current period disposable sales volumes related to the transition from the Johnson and Johnson catheter to our proprietary MAGiC catheter". This is the single most important sentence in the file: the revenue decline is a known, transitional supply substitution — not demand evaporation — and the margin expansion (to 60%) confirms the mix is shifting toward owned, higher-margin product. APT (acquired 2024) is the other driver of the disposables base.

Decelerating or accelerating? FY2025 was decelerating-into-trough then reversed negative in Q1 2026 — but management frames this as a J-curve, not a decline, with the inflection in H2 2026 (see Lens 5).

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q1 2026, filed 2026-05-13)

The numbers:

• Revenue $6.29M, −16% YoY (vs $7.47M Q1 2025) [L226].
• Gross margin 60% (up from 54%) — cost of revenue $2.50M [L231, L2222].
• Opex: R&D $2.40M (+2%), S&M $2.62M (−17%, lower headcount), G&A $4.76M (+6%, driven by contingent-consideration remeasurement and Robocath deal costs) [L236-238, L2232-2245].
• Net loss $(5.86)M (essentially flat vs $(5.82)M) [L244]. Net loss to common $(6.17)M (the gap is the ~$0.31M/qtr Series A preferred dividend) [L247].
• Operating cash burn $(3.44)M for the quarter (up from $(1.78)M, on working-capital changes) [L333, L2300].

Balance sheet:

• Cash $14.6M (up from $13.4M at YE25), funded by a Q1 ATM equity raise of ~$4.6M (2.0M shares at ~$2.28) [L295, L2316].
• No debt [L2305-ish, "did not have any debt"].

Guidance / outlook (the falsifiable crux) — reaffirmed on the call:

• FY2026 revenue >$40M, double-digit growth.
• Q3 and Q4 each expected to exceed $10M — i.e. a hockey-stick from the $6.3M Q1 trough.
• MAGiC "demand far exceeds supply"; manufacturing ramping toward 500 catheters/month by year-end.

Market reaction: modest; the stock sits at ~$1.77 (mid-June 2026), near the low end of its range, signalling the market is not yet paying for the H2 ramp — it wants to see Q2/Q3 evidence.

Unusual vs. own history: a revenue decline is unusual after +20% FY2025, but it is the first quarter of a deliberate product transition. The 6pp gross-margin jump in the same quarter is the tell that the transition is working at the unit level even as volume dips. Flag: burn nearly doubled QoQ — at $3.4M/qtr against $14.6M cash, the runway math is tight (~4 quarters before the next raise, absent the H2 ramp).

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research shelf (transcripts=0); sourced from web coverage of the Q1 2026 call.

• Management tone — unusually bullish on strategy, candid on near-term strain. CEO Fischel: the company is "going through one of the most exciting periods in Stereotaxis' history," citing US/EU/China regulatory approvals across a "new ecosystem of robotic surgery products".
• The recurring frame: Q1 results "did not yet reflect" the major commercial transition (new approvals, MAGiC, GenesisX launch). Management is explicitly asking investors to look through the trough.
• What they keep saying: manufacturing ramp, recurring/high-margin disposables, "demand far exceeds supply" for MAGiC, a long-term vision of remote/automated robotic treatment of stroke and cardiovascular disease (the Robocath rationale).
• Sentiment shift: the analyst read is "clear strategic momentum mixed with stubborn near-term financial strain" — falling revenue, higher burn, execution risk that "could test investor patience over several quarters".

Net: a credible, technically-fluent CEO selling a J-curve. The risk is the classic small-cap-medtech pattern of "the inflection is always two quarters out." The 2026 guidance is specific enough ($40M, Q3/Q4 >$10M each) to be scoreable — which is healthy.

Lens 7 · Comps

Peer universe pulled from the research index robotics topic, filtered to medical/surgical robotics (the humanoid and lidar names in the bucket are not comparable). Multiples `` with date, or n/a.

Read: On sales, STXS at ~4.4–5.5x P/S is roughly in line with PRCT (~4.9x) despite being ~8x smaller and earlier in its recurring-revenue inflection — so it is not obviously cheap on a sales multiple. The bull case is not "cheap today"; it is "the $40M guide → $60M+ → a recurring mix that eventually earns an ISRG-style multiple." ISRG's ~18x P/S and ~57x P/E is the aspirational end-state the razor-and-blade model could command if STXS ever reaches durable profitability — a multi-year, heavily conditional "if."

Lens 8 · Stock-Price Catalysts (what moves STXS)

STXS is a sub-$200M micro-cap; it trades on regulatory milestones, system orders, and capital raises, not macro. Pattern ``:

• GenesisX first order (Jan 30, 2025, European hospital) — framed as a key milestone.
• GenesisX FDA 510(k) clearance (Nov 10, 2025) — the stock traded flat on the day; YTD-through-mid-Nov 2025 +6.6%. Tells you regulatory wins are increasingly expected and pre-positioned.
• MAGiC catheter FDA approval (January 2026) — removed the final regulatory barrier to a fully proprietary system.
• MAGiC Sweep FDA 510(k) (July 2025).
• Robocath acquisition announced (April 14, 2026) — strategic expansion into coronary/neuro robotics.
• Equity raises (July 2025 raise; Q1 2026 ATM) — dilutive, a recurring overhang.

What the pattern reveals: the market has stopped paying up for regulatory clearances (they're now in the price) and is waiting for proof of the commercial ramp — i.e. the Q2/Q3 2026 revenue prints and MAGiC unit volumes are the next real catalysts. A clean Q3 >$10M would be the thesis-confirming event; a miss would trigger dilution fears.

---

Phase C — Judge people & books

Lens 9 · Management

CEO & Chairman David L. Fischel — the central figure, and a genuinely differentiated one:

1. Track record / archetype: activist-investor-turned-operator. Spent 10+ years as a medical-device portfolio manager at DAFNA Capital Management (a healthcare hedge fund, and a major STXS holder), CPA/CFA/CAIA, UCLA applied math. Became Chairman & CEO Feb 2017. On taking over he paid off the company's debt, cut ineffective middle/senior management, shifted board comp from cash to stock, and refocused on internal innovation. Stock is up ~10x off the bottom of his tenure — a real, quantified turnaround (from near-death to a credible product company), though off a distressed base and still pre-profit.
2. Tenure & skin in the game: ~9 years; deeply tied to the largest holder (DAFNA). The alignment is unusually high — see the PSU below.
3. Capital allocation: debt eliminated (the company has no debt today ); two tuck-in acquisitions (APT 2024 for the disposables base; Robocath 2026 for coronary/neuro robotics); funds the burn via equity (dilutive but solvency-preserving). ROE/ROIC are negative (accumulated deficit $589M) — but that is a pre-inflection medtech reality, not value destruction on his watch.
4. Red flags: the CEO Performance Award — a 10-year award of up to 13,000,000 PSUs. SBC attributable to it was ~$7.1M/yr. If fully earned, Fischel would own ~10% post-dilution. This is double-edged: world-class alignment, but a meaningful dilution overhang and an explicit anti-takeover device — the 10-K concedes the PSU "may discourage a change in control... even if beneficial to stockholders". A potential acquirer of this asset (a logical outcome for a sub-scale robotics platform) is partly blocked by its own CEO's incentive plan.
5. CFO Kimberly Peery — appointed Oct 2019, with the company since 2003 (deep institutional knowledge).

Net: a high-quality, financially-sophisticated, well-aligned operator who has already done one turnaround. The governance blemishes (the PSU's size and anti-takeover effect, plus the DAFNA relationship) are the things a buyer must underwrite — not deal-breakers, but eyes-open.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst. The accounts are clean for a company of this profile, but there are structural flags inherent to a perpetually-pre-profit micro-cap. All figures `` unless noted.

• Going concern / solvency (the real risk). The 10-K states 2026 opex "will exceed its 2026 gross margin" and the company "expects to continue to incur operating losses and negative cash flows" until revenues suffice; liquidity depends on adoption + new placements, with the plan being expense control + "raising additional funds through debt or equity financing". With $14.6M cash and $(3.4)M quarterly burn, this is a ~1-year-runway situation that requires either the H2 ramp or another raise. Cumulative net losses since inception ~$589.2M.
• Revenue recognition: systems revenue recognized at sale (with installation/warranty cost accruals); service/software deferred and amortized over ~1 year. Standard, conservative; ~$11.4M of remaining performance obligations / deferred at YE25. No aggressive recognition detected.
• Backlog erosion (yellow flag): system backlog fell to $9.1M (YE25) from $14.4M (YE24) — a ~37% decline. ~78% expected to convert in 2026. Shrinking backlog into a year management guides to >$40M is a tension worth watching: the guide leans heavily on new orders + disposable ramp, not the existing book.
• Contingent consideration: APT (and now Robocath) carry milestone-based contingent payments remeasured through G&A — a source of non-operational G&A volatility (a Q1 2026 driver). Classified Level 3 (unobservable) fair value.
• SBC flatters nothing here — the company reports GAAP losses; the ~$7M/yr PSU SBC is a real economic dilution cost, fully in the GAAP net loss. No non-GAAP sleight of hand detected.
• Deferred tax: 100% valuation allowance on DTAs (history of losses, Section 382 limits) — appropriately conservative.
• Series A Convertible Preferred (6% dividend) sits in mezzanine; creates the ~$1.3M/yr gap between net loss and net-loss-to-common and a small structural drag.
• Minor controls note: the company disclosed it inadvertently omitted the CFO's Rule 10b5-1 plan disclosure in a prior 10-Q (corrected) — immaterial, but noted.

Regulatory findings (required sub-section):

• SEC Litigation Releases: none. AAERs: none. Verified via SEC EDGAR EFTS (LR + AAER) for 2021-06-21 → 2026-06-21.
• Item 3 Legal Proceedings (10-K): "The Company is involved from time to time in various lawsuits and claims arising in the normal course of business" — no material litigation disclosed.
• Non-SEC enforcement (FTC/DOJ/FDA): web search returned no material enforcement actions, consent decrees, fines, or penalties against Stereotaxis. (FDA interaction is product-clearance, not enforcement — all recent FDA news is clearances, not warning letters.)
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-21. The book is clean; the only "red flag" is the structural going-concern/dilution dynamic, which is fully disclosed.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

STXS is loss-making; the relevant projection is revenue trajectory + path to cash-flow breakeven, not an EPS multiple. Built bottom-up from the latest actuals + guidance. Outputs ``; inputs labeled.

Anchor: Q1 2026 actual revenue $6.29M. Management guide: FY2026 >$40M, Q3 & Q4 each >$10M. MAGiC ramp to ~500 catheters/month by YE.

FY2026 (base / bull / bear):

• Base ~$38M. Just under the $40M target — credible if MAGiC supply lands roughly on schedule.
• Bull ~$42M. Gross margin drifts to ~58–62% on owned-catheter mix → meaningfully narrower losses.
• Bear ~$30M. Forces another dilutive raise in H1 2027.

FY2027 / FY2028 (directional):

• Base FY2027 ~$50M, FY2028 ~$62M. Gross margin → mid-60s% as systems become a smaller share.
• The number that actually matters — runway-to-breakeven: at ~$40M revenue, 55–60% GM ($23M gross profit) against ~$45M+ opex, the company is still loss-making. Cash-flow breakeven plausibly needs ~$60–70M revenue at this cost structure. That implies at least one more capital raise between here and self-funding, regardless of the ramp — the bear's strongest structural point.

Brier forecast (NOT logged — --watchlist rule skips forecast.ts create): the scoreable base call would be "STXS FY2026 revenue ≥ $38M, p≈0.55, resolves 2027-03 (FY26 10-K)." The crisper binary: "STXS Q3 2026 revenue ≥ $10M (management's own bar), p≈0.50." Left unlogged per breadth-mode rules; flagged here for a future /thesis pass.

Lens 12 · Bull vs Bear

Bull case. Stereotaxis has, for the first time in its ~30-year history, a complete proprietary stack — GenesisX (a robot that installs in an unmodified cath lab, 80% smaller cabinet, standard power, no anchoring ) plus MAGiC (its own ablation catheter) plus MAGiC Sweep (its own mapping catheter). The decade-long structural handicap — renting its key blade from competitor J&J — is gone. The razor-and-blade flywheel can finally turn: every GenesisX placed pulls high-margin (66–67%) proprietary disposables, and "demand far exceeds supply" means the only governor is the company's own manufacturing ramp, which is a solvable problem. Gross margin already moved 54%→60% in Q1 as the mix shifted. Add Robocath's optionality into the vastly larger coronary intervention + neurovascular (stroke) markets, a top-tier aligned CEO who already 10x'd the stock once, no debt, and a Street that sees $4.00–$4.50 (125–150% upside). This is the "baby Intuitive Surgical" thesis — a recurring-revenue medical-robotics compounder caught at the inflection.

Bear case (permanent-impairment risks). (1) The ramp is the entire thesis and it is unproven — guidance asks you to underwrite Q3/Q4 each >$10M from a $6.3M Q1; small-cap medtech "the inflection is two quarters out" promises break routinely. (2) Solvency math is unforgiving — $14.6M cash, $3.4M/qtr burn, no debt capacity it wants to use, and a structurally pre-profit P&L means dilution is near-certain (likely another raise within ~12 months) at a depressed ~$1.77 share price; the Series A pref and the 13M-PSU overhang compound the share-count creep. (3) Backlog is shrinking ($14.4M→$9.1M) into a year that guides up — the order book isn't corroborating the hockey stick. (4) Pulse Field Ablation (PFA) is reshaping EP — the fastest-growing ablation modality, and the 10-K lists PFA explicitly as competition the RMN "is not currently compatible" with in some configurations; if EP volume migrates to PFA workflows that don't favor magnetic navigation, the addressable base erodes.

Pre-mortem (it's Dec 2027, the thesis broke): the MAGiC manufacturing ramp hit a quality/yield wall and never reached 500/month; FY2026 came in ~$32M (flat), Q3 missed the $10M bar; the company raised equity twice at ~$1.50, the share count ballooned ~25%; PFA adoption pulled complex-ablation volume away from RMN; the Robocath integration consumed management bandwidth and cash for a still-pre-revenue European asset. The stock is sub-$1.

Are the multiples too high? On current sales, ~5x P/S for a declining-revenue quarter is not cheap — it already embeds the ramp. The valuation is reasonable only if you believe the H2 inflection.

Contrarian view — what the market refuses to see: the bears anchor on the $6.3M Q1 and the burn; what they under-weight is that this is the first quarter in company history where Stereotaxis owns its full economic stack, and the J&J catheter overhang — the thing that capped this company for a decade — is finally resolved. The market is pricing the transition risk but not the post-transition margin structure (owned catheters at ~67% GM on a growing installed base). If the ramp lands, the re-rate is non-linear because both revenue growth and gross margin inflect together.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the model: the company has burned through $589M of cumulative losses over ~30 years and has never turned an annual profit. The base rate for "this time the inflection is real" at a serial-dilution micro-cap is poor. The whole bull case rests on a manufacturing ramp the company has not yet demonstrated at volume.
• Revenue concentration / fragility: while no single customer is >10%, revenue is concentrated in one clinical application (cardiac EP) and one geography (US). A modality shift (PFA) or a single bad year of hospital capital budgets hits the whole company.
• Why the moat is weaker than bulls think: the RMN moat is over a niche. Magnetic navigation has existed for two decades and never crossed into mass EP adoption — most ablations are still done manually or, increasingly, with PFA. If magnetic navigation were a must-have, the installed base would be far larger than a company doing $32M/yr implies. The moat protects a small, slow-growing castle.
• Most dangerous underestimated competitor: not another magnetic-robot maker — it's the PFA wave (Boston Scientific, Medtronic, J&J/Biosense) reshaping EP economics and workflow. Stereotaxis is a navigation layer; if the ablation energy source and workflow move to PFA single-shot systems that don't need (or don't integrate with) magnetic navigation, RMN's relevance narrows.
• Worst capital-allocation / governance moves: the 13M-PSU CEO award is enormous relative to a ~100M-share, $177M-cap company — and it doubles as an anti-takeover poison pill that could block the most logical outcome (acquisition by a strategic). The DAFNA-CEO entanglement means the largest holder and the CEO are effectively the same interest.
• What must hold for $1.77, let alone $4: that the H2 ramp lands, MAGiC reaches ~500/month, FY2026 hits ~$40M, and the company reaches breakeven before dilution destroys the per-share story. That's a stack of conditional "ifs."
• If growth disappoints 20–30%: FY2026 lands ~$28–30M (flat-to-down), the $40M guide is missed, confidence in the ramp narrative breaks, and a forced raise at a low price re-rates the stock down 30–50%. There is little valuation support — no earnings, thin cash.
• Single scenario that permanently impairs: MAGiC manufacturing fails to scale (yield/quality), J&J catheter supply ends as threatened, and the installed base is left without an adequate ablation catheter — revenue from the disposable base craters while the company is still burning. Plausibility: low-to-moderate — MAGiC is already cleared and in commercial use ("first MAGiC procedure" announced), so total failure is unlikely; a slow ramp is the more realistic and still-painful outcome.

Lens 14 · Management Questions (ordered by information value)

1. MAGiC manufacturing ramp: what is the current monthly catheter output vs. the 500/month YE target, and what is the single biggest constraint (yield, components, cleanroom capacity) — and what's your confidence interval on hitting Q3 >$10M?
2. J&J catheter supply: is Biosense Webster still supplying the legacy catheters in 2026, and what % of your installed base could be left without an adequate ablation catheter if that supply stops before MAGiC fully ramps?
3. Cash runway: at the current ~$3.4M/quarter burn, when do you expect to need additional capital, and is the plan equity, debt, or a strategic partnership — i.e. should we model another raise in the next 12 months?
4. Backlog: system backlog fell from $14.4M to $9.1M — reconcile that with FY2026 guidance of >$40M. How much of the guide depends on orders not yet in backlog?
5. Path to breakeven: at what revenue level does this business reach cash-flow breakeven at the current cost structure, and what's the realistic year?
6. PFA threat: as pulse-field ablation reshapes EP, how does RMN integrate with (or get displaced by) PFA workflows — is magnetic navigation complementary or competitive to where the ablation market is heading?
7. GenesisX adoption: what's the system-placement pipeline for 2026, and is the "installs in an unmodified cath lab" advantage actually shortening the sales cycle in practice?
8. Robocath: what is Robocath's current revenue/burn, what does it cost to integrate and commercialize, and when does it become revenue-additive rather than cash-consumptive?
9. Recurring revenue mix: as MAGiC scales, where does the disposables/service gross margin settle, and what's the steady-state blended gross margin you're targeting?
10. The PSU award: how do you respond to the concern that the 13M-share CEO performance award is both a large dilution overhang and an anti-takeover device that could block a value-maximizing sale?
11. Geographic expansion: beyond the US, where (Europe, China, Japan) do you see MAGiC/GenesisX driving the next leg, and what are the regulatory timelines?
12. Competitive catheter response: if MAGiC succeeds, what stops Biosense Webster or another major from building a competing magnetically-enabled catheter, and how defensible is your catheter IP?
13. Utilization: what is procedure utilization per installed system trending toward, and what drives a hospital from a few procedures/month to a high-volume RMN program?
14. Capital allocation: with no debt and an equity-funded model, how do you weigh further M&A (post-Robocath) against conserving cash to reach breakeven?
15. Long-term vision: the "remote/automated robotic treatment of stroke" vision is large but distant — what are the concrete 24-month milestones that move it from narrative to revenue?

---